# Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis

> **NCT00035997** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 261 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Zometa

## Key facts

- **NCT ID:** NCT00035997
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2004-01
- **Final completion:** 2004-01
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2009-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00035997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00035997, "Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00035997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*